Article Top Ad

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE,
PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN
WHOLE OR IN PART, IN OR INTO THE UNITED STATES

TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP;
OTCQB:ASPCF) announced today its shares have been approved to be quoted
on the OTCQB Venture Market and will trade under the symbol “ASPCF”
effective immediately. Real-time information, quotes and the trading
statistics can be found at www.otcmarkets.com.
This is the latest development in the Company’s strategy to provide
improved channels for market participation.

“Listing on the OTCQB Venture is part of a long-term strategy to
introduce the Company to a broader audience,” said Ed Gudaitis,
President & CEO of Acerus. “We believe trading on the OTCQB will help us
enhance liquidity by providing our current and future American investors
with a trading platform.”

This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities. The securities
described herein have not been and will not be registered under the
United States Securities Act of 1933, as amended, or the securities laws
of any state and may not be offered or sold within the United States or
to or for the benefit or account of U.S. persons, absent such
registration or an applicable exemption from such registration
requirements.

About Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Corporation is a Canadian-based specialty
pharmaceutical company focused on the development, manufacture,
marketing and distribution of innovative, branded products that improve
patient experience, with a primary focus in the field of men’s and
women’s health. The Company commercializes its products via its own
salesforce in Canada, and through a global network of licensed
distributors in the U.S. and other territories.

In addition to the listing on OTCQB, Acerus’ shares trade on TSX under
the symbol ASP. For more information, visit www.aceruspharma.com
and follow us on Twitter
and LinkedIn.

Forward-Looking Information

Information in this press release that is not current or historical
factual information may constitute forward-looking information within
the meaning of securities laws. Implicit in this information are
assumptions regarding our future operational results. These assumptions,
although considered reasonable by the company at the time of
preparation, may prove to be incorrect. Readers are cautioned that
actual performance of the company is subject to a number of risks and
uncertainties, and could differ materially from what is currently
expected as set out above. For more exhaustive information on these
risks and uncertainties you should refer to our annual information form
dated March 4, 2019 that is available at
www.sedar.com.
Forward-looking information contained in this press release is based on
our current estimates, expectations and projections, which we believe
are reasonable as of the current date. You should not place undue
importance on forward-looking information and should not rely upon this
information as of any other date. While we may elect to, we are under no
obligation and do not undertake to update this information at any
particular time, whether as a result of new information, future events
or otherwise, except as required by applicable securities laws.

Contacts

Robert Motz
Chief Financial Officer
Acerus Pharmaceuticals
Corporation
[email protected]
(905)
817-8288